Research ExplorerPublicationsNew directions in cellular therapy of cancer: a summary of t...

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

Standard

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. / Stroncek, David F; Berger, Carolina; Cheever, Martin A; Childs, Richard W; Dudley, Mark E; Flynn, Peter; Gattinoni, Luca; Heath, James R; Kalos, Michael; Marincola, Francesco M; Miller, Jeffrey S; Mostoslavsky, Gustavo; Powell, Daniel J; Rao, Mahendra; Restifo, Nicholas P; Rosenberg, Steven A; O'Shea, John; Melief, Cornelis J M.

In: J TRANSL MED, Vol. 10, 15.03.2012, p. 48.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stroncek, DF, Berger, C, Cheever, MA, Childs, RW, Dudley, ME, Flynn, P, Gattinoni, L, Heath, JR, Kalos, M, Marincola, FM, Miller, JS, Mostoslavsky, G, Powell, DJ, Rao, M, Restifo, NP, Rosenberg, SA, O'Shea, J & Melief, CJM 2012, 'New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer', J TRANSL MED, vol. 10, pp. 48. https://doi.org/10.1186/1479-5876-10-48

APA

Stroncek, D. F., Berger, C., Cheever, M. A., Childs, R. W., Dudley, M. E., Flynn, P., Gattinoni, L., Heath, J. R., Kalos, M., Marincola, F. M., Miller, J. S., Mostoslavsky, G., Powell, D. J., Rao, M., Restifo, N. P., Rosenberg, S. A., O'Shea, J., & Melief, C. J. M. (2012). New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J TRANSL MED, 10, 48. https://doi.org/10.1186/1479-5876-10-48

Vancouver

Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J TRANSL MED. 2012 Mar 15;10:48. https://doi.org/10.1186/1479-5876-10-48

Bibtex

@article{94824ec08ec04714b0d611c32c6b5233,
title = "New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer",
abstract = "A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more na{\"i}ve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.",
keywords = "Cell Transplantation/methods, Humans, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating/immunology, Melanoma/therapy, Neoplasms/therapy",
author = "Stroncek, {David F} and Carolina Berger and Cheever, {Martin A} and Childs, {Richard W} and Dudley, {Mark E} and Peter Flynn and Luca Gattinoni and Heath, {James R} and Michael Kalos and Marincola, {Francesco M} and Miller, {Jeffrey S} and Gustavo Mostoslavsky and Powell, {Daniel J} and Mahendra Rao and Restifo, {Nicholas P} and Rosenberg, {Steven A} and John O'Shea and Melief, {Cornelis J M}",
year = "2012",
month = mar,
day = "15",
doi = "10.1186/1479-5876-10-48",
language = "English",
volume = "10",
pages = "48",
journal = "J TRANSL MED",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

AU - Stroncek, David F

AU - Berger, Carolina

AU - Cheever, Martin A

AU - Childs, Richard W

AU - Dudley, Mark E

AU - Flynn, Peter

AU - Gattinoni, Luca

AU - Heath, James R

AU - Kalos, Michael

AU - Marincola, Francesco M

AU - Miller, Jeffrey S

AU - Mostoslavsky, Gustavo

AU - Powell, Daniel J

AU - Rao, Mahendra

AU - Restifo, Nicholas P

AU - Rosenberg, Steven A

AU - O'Shea, John

AU - Melief, Cornelis J M

PY - 2012/3/15

Y1 - 2012/3/15

N2 - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

AB - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

KW - Cell Transplantation/methods

KW - Humans

KW - Immunotherapy, Adoptive

KW - Lymphocytes, Tumor-Infiltrating/immunology

KW - Melanoma/therapy

KW - Neoplasms/therapy

U2 - 10.1186/1479-5876-10-48

DO - 10.1186/1479-5876-10-48

M3 - SCORING: Journal article

C2 - 22420641

VL - 10

SP - 48

JO - J TRANSL MED

JF - J TRANSL MED

SN - 1479-5876

ER -